PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
PDL BioPharma Announces First Quarter 2016 Financial Results
PDL BioPharma Announces 2016 Second Quarter Dividend
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016
PDL BioPharma to Hold Annual Meeting of Stockholders on June 2, 2016